All patients
Age < 65y (younger) Age > 65y cancer type (metastatic) cancer type (recurrent) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mHNSCC - 1st line (L1), pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.63; 0.94]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.63 [0.51; 0.77]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.60 [0.44; 0.81]
0.68 [0.58 ; 0.79 ] KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 3 28% 1,263 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.72 [0.60; 0.87]
0.72 [0.60 ; 0.87 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 559 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.92 [0.77; 1.10]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.82 [0.67; 1.00]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.73 [0.55; 0.97]
0.85 [0.75 ; 0.95 ] KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 3 0% 1,263 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.69; 1.37]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 1.03 [0.71; 1.49]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 1.21 [0.72; 2.05]
1.03 [0.82 ; 1.30 ] KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 3 0% 1,272 moderate not evaluable AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.69; 1.46]
1.00 [0.69 ; 1.46 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.21 [0.71; 2.07]
1.21 [0.71 ; 2.07 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.27 [0.89; 1.83]
1.27 [0.89 ; 1.83 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable TRAE (any grade)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.71 [0.30; 1.72]
0.71 [0.30 ; 1.72 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.12 [0.78; 1.61]
1.12 [0.78 ; 1.61 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.45 [0.57; 3.65]
1.45 [0.57 ; 3.65 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.89; 2.14]
1.38 [0.89 ; 2.14 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
1.22 [0.40 ; 3.67 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.30 [0.92; 1.82]
1.30 [0.92 ; 1.82 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.08 [0.07 ; 62.36 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.15; 7.44]
1.04 [0.15 ; 7.44 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.59 [0.64; 3.94]
1.59 [0.64 ; 3.94 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.62 [0.15; 2.62]
0.62 [0.15 ; 2.62 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.08 [0.07 ; 62.36 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.85 [0.87; 3.97]
1.85 [0.87 ; 3.97 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [1.15; 3.13]
1.90 [1.15 ; 3.13 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.08 [0.07 ; 62.36 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.08 [0.07 ; 62.36 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.34 [0.07; 1.71]
0.34 [0.07 ; 1.71 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.51 [0.21; 1.20]
0.51 [0.21 ; 1.20 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.88 [0.55; 1.41]
0.88 [0.55 ; 1.41 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.03 [1.04; 3.97]
2.03 [1.04 ; 3.97 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.08 [0.07 ; 62.36 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.52 [0.02; 15.54]
0.52 [0.02 ; 15.54 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.47; 2.01]
0.97 [0.47 ; 2.01 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.85 [0.56; 1.30]
0.85 [0.56 ; 1.30 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.08 [0.07 ; 62.36 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.63 [0.51 ; 13.67 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.06 [0.01 ; 0.44 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.10 [0.02; 0.45]
0.10 [0.02 ; 0.45 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.11 [0.03; 0.35]
0.11 [0.03 ; 0.35 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.40 [1.11; 5.16]
2.40 [1.11 ; 5.16 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.58; 1.89]
1.04 [0.58 ; 1.89 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.47 [0.46; 4.68]
1.47 [0.46 ; 4.68 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.09 [0.19; 23.16]
2.09 [0.19 ; 23.16 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14]
0.41 [0.08 ; 2.14 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.63 [0.51 ; 13.67 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.65 [1.10; 2.49]
1.65 [1.10 ; 2.49 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.41; 2.66]
1.04 [0.41 ; 2.66 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [1.00; 1.94]
1.39 [1.00 ; 1.94 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.37 [0.59; 3.18]
1.37 [0.59 ; 3.18 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.39; 2.81]
1.04 [0.39 ; 2.81 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [0.31; 6.28]
1.39 [0.31 ; 6.28 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.52 [0.75; 3.08]
1.52 [0.75 ; 3.08 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.61 [0.84; 3.11]
1.61 [0.84 ; 3.11 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.43 [0.89; 2.29]
1.43 [0.89 ; 2.29 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.71 [1.09; 2.67]
1.71 [1.09 ; 2.67 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 17.10 [0.98; 299.27]
17.10 [0.98 ; 299.27 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14]
0.41 [0.08 ; 2.14 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Leucopenia AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.57 [0.25; 1.31]
0.57 [0.25 ; 1.31 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.11 [0.76; 1.63]
1.11 [0.76 ; 1.63 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.97 [1.02; 3.78]
1.97 [1.02 ; 3.78 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.98 [0.48; 1.98]
0.98 [0.48 ; 1.98 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.90 [0.48; 1.67]
0.90 [0.48 ; 1.67 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.80 [0.53; 1.22]
0.80 [0.53 ; 1.22 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.38; 1.53]
0.77 [0.38 ; 1.53 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.06 [0.01 ; 0.44 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [0.63; 5.75]
1.90 [0.63 ; 5.75 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.56 [1.33; 4.91]
2.56 [1.33 ; 4.91 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Sepsis AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.10 [0.38; 11.53]
2.10 [0.38 ; 11.53 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
1.22 [0.40 ; 3.67 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.52 [1.18; 5.39]
2.52 [1.18 ; 5.39 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.56; 1.78]
1.00 [0.56 ; 1.78 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Vascular disorders AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.57 [0.80; 3.09]
1.57 [0.80 ; 3.09 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.31 [0.51; 3.37]
1.31 [0.51 ; 3.37 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Weight decreased AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 2.83 [0.74; 10.76]
2.83 [0.74 ; 10.76 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 06:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 277,102,109
- treatments: 875